The short version of Cyclic AMP fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-24 and is reviewed periodically as new material appears.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
== Adverse effects == The most common side effects include headache, fever, fall, cough, vomiting, abdominal pain, cold symptoms (nasopharyngitis) and nausea. In animal studies, no significant changes were seen in the male reproductive system of monkeys and mice following weekly subcutaneous administration. According to the reports obtained from the clinical trials, pain at the site of intravenous administration, back pain, oropharyngeal pain, sprain in ligaments, diarrhea, dizziness, contusion, flu, ear infection, rhinitis, skin abrasion, tachycardia, and constipation occurred at an elevated frequency in the treatment group, as compared to their placebo counterparts. Hypersensitivity reactions, including rash, fever, itching, hives, skin irritation (dermatitis) and skin peeling (exfoliation), have occurred in people who were treated with golodirsen. Renal toxicity was observed in animals who received golodirsen. Although renal toxicity was not observed in the clinical studies with golodirsen, potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Renal function should be monitored in those taking golodirsen.
Chloral hydrate is a geminal diol with the formula Cl3C−CH(OH)2. It was first used as a sedative and hypnotic in Germany in the 1870s. Over time it was replaced by safer and more effective alternatives but it remained in use in the United States until at least the 1970s. It sometimes finds usage as a laboratory chemical reagent and precursor. It is derived from chloral (trichloroacetaldehyde) by the addition of one equivalent of water.
All meitnerium isotopes are extremely unstable (radioactive); in general, heavier isotopes are more stable than the lighter. The most stable known isotope, 278Mt (half-life 4.5 seconds), is also the heaviest known. The unconfirmed 282Mt is even heavier and seems to have a longer half-life, 67 seconds. With a half-life of 0.8 seconds, the next most stable known isotope is 270Mt. 276Mt and 274Mt have half-lives of 0.62 and 0.64 seconds respectively. 277Mt, created as the final decay product of 293Ts for the first time in 2012, was observed to undergo spontaneous fission, half-life 5 milliseconds. Preliminary data analysis considered the possibility that this fission is instead from 277Hs, for it also has a half-life of a few milliseconds, and could come from undetected electron capture somewhere in the decay chain. This possibility was later deemed very unlikely based on observed decay energies of 281Ds and 281Rg and the short half-life of 277Mt, although there is still some uncertainty of the assignment. Regardless, the rapid fission of 277Mt and 277Hs is strongly suggestive of a region of instability for superheavy nuclei with N = 168–170. The existence of this region, characterized by a decrease in fission barrier height between the deformed shell closure at N = 162 and spherical shell closure at N = 184, is consistent with theoretical models.
Brain-specific angiogenesis inhibitor InterPro: IPR008077 BAI1; BAI2; BAI3 CD97 antigen InterPro: IPR003056 CD97 EMR hormone receptor InterPro: IPR001740 CELSR1; CELSR2; CELSR3; EMR1; EMR2; EMR3; EMR4 GPR56 orphan receptor InterPro: IPR003910 GPR56; GPR64; GPR97; GPR110; GPR111; GPR112; GPR113; GPR114; GPR115; GPR123; GPR125; GPR126; GPR128; GPR133; GPR144; GPR157 Latrophilin receptor InterPro: IPR003924 ELTD1; LPHN1; LPHN2; LPHN3 Ig-hepta receptor InterPro: IPR008078 GPR116
=== Sport === Donough O'Brien (1879–1953), was a Welsh-born Irish cricketer. Ray Williams (born 1959), is a weightlifting Commonwealth Games gold medallist. Tony Roberts (born 1969), is Welsh international footballer with 614 club caps Gareth Evans (born 1986), weightlifter, Commonwealth gold medalist and 2012 Summer Olympics, lives in the town. Alex Lynch (born in 1995), a footballer with over 100 club caps, educated in Ysgol Uwchradd Caergybi.
Sources: en.wikipedia.org
== Interfacial potential == An interface is defined as the common boundary formed between two different phases, such as between a solid and gas. Electric potential, or charge, is the result of an object's capacity to be moved in an electric field. An interfacial potential is thus defined as a charge located at the common boundary between two phases (for example, an amino acid such as glutamate on the surface of a protein can have its side chain carboxylic acid deprotonated in environments with pH greater than 4.1 to produce a charged amino acid at the surface, which would create an interfacial potential). Interfacial potential is responsible for the formation of the electric double layer, which has a broad range of applications in what is termed electrokinetic phenomena. The development of the theory of the electric double layer is described below.
== Further reading == Bowie, Andrew. Adorno and the Ends of Philosophy, Cambridge: Polity 2013 Brunger, Jeremy (5 May 2015). "The Administered World of Theodor Adorno". Numéro Cinq magazine. Delanty, Gerard (ed.) Theodor W. Adorno. London: SAGE, 2004. Edwards, Peter. "Convergences and Discord in the Correspondence Between Ligeti and Adorno", Music & Letters, 96/2, 2015. Gerhardt, Christina Archived 17 April 2022 at the Wayback Machine (ed.). "Adorno and Ethics". New German Critique 97 (2006): 1–3. Hogh, Philip. Communication and Expression: Adorno's Philosophy of Language. Translated by Antonia Hofstätter. London and New York: Rowman & Littlefield International, 2017. Gordon, Peter. Adorno and Existence. Cambridge, MA/London: Harvard University Press, 2016. Hohendahl, Peter Uwe. Prismatic Thought: Theodor W. Adorno. Lincoln, Nebr.: University of Nebraska Press, 1995. Jarvis, Simon. Adorno: A Critical Introduction. Cambridge: Polity, 1998. Jay, Martin. The Dialectical Imagination: A History of the Frankfurt School and the Institute for Social Research 1923–1950. Berkeley and Los Angeles: University of California Press, 1996. Jay, Martin. Adorno. Cambridge, Mass: Harvard University Press, 1984. Jeffries, Stuart. Grand Hotel Abyss: The Lives of the Frankfurt School. New York: Verso, 2016. Morgan, Ben. "The project of the Frankfurt School", Telos, Nr. 119 (2001), 75–98 Paddison, Max. Adorno's Aesthetics of Music. Cambridge: Cambridge University Press, 1993. Paddison, Max. Adorno, Modernism and Mass Culture: Essays on Critical Theory. London: Kahn & Averill, 2004.
Within the dorsal horn of the spinal cord, activated astrocytes have the ability to respond to almost all neurotransmitters and, upon activation, release a multitude of neuroactive molecules such as glutamate, ATP, nitric oxide (NO), and prostaglandins (PG), which in turn influences neuronal excitability. The close association between astrocytes and presynaptic and postsynaptic terminals as well as their ability to integrate synaptic activity and release neuromodulators has been termed the tripartite synapse. Synaptic modulation by astrocytes takes place because of this three-part association. A 2023 study suggested astrocytes, previously underexplored brain cells, could be key to extending wakefulness without negative effects on cognition and health.
When adhered to a surface, neutrophil granulocytes have an average diameter of 12–15 micrometers (μm) in peripheral blood smears. In suspension, human neutrophils have an average diameter of 8.85 μm. With the eosinophil and the basophil, they form the class of polymorphonuclear cells, named for the nucleus's multilobulated shape (as compared to lymphocytes and monocytes, the other types of white cells). The nucleus has a characteristic lobed appearance, the separate lobes connected by chromatin. The nucleolus disappears as the neutrophil matures, which is something that happens in only a few other types of nucleated cells. Up to 17% of female human neutrophil nuclei have a drumstick-shaped appendage which contains the inactivated X chromosome. In the cytoplasm, the Golgi apparatus is small, mitochondria and ribosomes are sparse, and the rough endoplasmic reticulum is absent. The cytoplasm also contains about 200 granules, of which a third are azurophilic. Neutrophils will show increasing segmentation (many segments of the nucleus) as they mature. A normal neutrophil should have 3–5 segments. Hypersegmentation is not normal but occurs in some disorders, most notably vitamin B12 deficiency. This is noted in a manual review of the blood smear and is positive when most or all of the neutrophils have 5 or more segments.
=== Attachment to tendons === Muscles attach to tendons in a complex interface region known as the musculotendinous junction, also known as the myotendinous junction, an area specialised for the primary transmission of force. At the muscle-tendon interface, force is transmitted from the sarcomeres in the muscle cells to the tendon. Muscles and tendons develop in close association, and after their joining at the myotendinous junction they constitute a dynamic unit for the transmission of force from muscle contraction to the skeletal system.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.